Latest News

Clinical Trial Results 20 November 2026

Clinical Trial Results 20 November 2026

Clinical trial results 20 November 2026 span acute myeloid leukaemia, type 3 Gaucher disease, bladder cancer, depression and Alzheimer’s disease. SELLAS Life Sciences’ galinpepimut-S met its overall survival primary endpoint in acute myeloid leukaemia. The FDA...

read more

Latest News

OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

How does OLN324 compare with Vabysmo? In the only head-to-head data found, it dried the retina faster in diabetic macular oedema. However, differences in durability and vision were small. That evidence comes from a 164-patient Phase 1b trial, and no Phase 3 comparison...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Longevity Science Is Advancing. Can Clinical Care Keep Up?

Longevity Science Is Advancing. Can Clinical Care Keep Up?

The search to live longer is not new, but we are no longer looking for a hypothetical fountain of youth. Over the past few decades, research into metabolic health, longevity biomarkers, and more has led to longevity breakthroughs that open up new possibilities for...

read more
Lilly vs Novo in 2026: How the Obesity Market Has Shifted

Lilly vs Novo in 2026: How the Obesity Market Has Shifted

Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

read more
Longevity Science Is Advancing. Can Clinical Care Keep Up?

Longevity Science Is Advancing. Can Clinical Care Keep Up?

The search to live longer is not new, but we are no longer looking for a hypothetical fountain of youth. Over the past few decades, research into metabolic health, longevity biomarkers, and more has led to longevity breakthroughs that open up new possibilities for...

read more
Lilly vs Novo in 2026: How the Obesity Market Has Shifted

Lilly vs Novo in 2026: How the Obesity Market Has Shifted

Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Why Medical Electronics Are the Hardest E-Waste to Recycle

Why Medical Electronics Are the Hardest E-Waste to Recycle

Single-use medical electronics are one of the fastest-growing sources of electronic waste, yet almost none of their metals or batteries are recovered. The barrier is not technology. It is contamination, and the cost that comes with it. Every week or two, millions of...

read more
Weekly News Roundup | 9 November 2026

Weekly News Roundup | 9 November 2026

Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...

read more
Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma tumour risk moved from a label warning to a reported safety signal on 5 November 2026. Novartis said it had received nine tumour reports in treated patients since the 2019 approval. In two cases, the company said, there is evidence that vector DNA integrated...

read more
Clinical Trial Results 6 November 2026

Clinical Trial Results 6 November 2026

The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...

read more
Hygiene Poverty and the Overlooked Toileting Needs of Women

Hygiene Poverty and the Overlooked Toileting Needs of Women

If you had to choose between food and toilet paper, what would you choose? A UK report from In Kind Direct and The Hygiene Bank found that 47% of people experiencing hygiene poverty had gone without toilet roll, making it the most common product people went without....

read more

Further News

Biotech IPO Tracker 2026: How This Year’s Listings Have Traded

Biotech IPO tracker last updated: 10 November 2026. Prices as of the 6 November 2026 close. After a lean 2025, this year has reopened the US market for biotech flotations. This biotech IPO tracker lists every US-listed drug developer that has priced an initial public...

Creative Biolabs Helps Improve Reproducibility Across iPSC Organoid Studies

As iPSC-derived organoids gain importance in disease modeling and drug discovery, Creative Biolabs highlights iPSC differentiation consistency, cell characterization, and application-specific validation to help researchers develop more reliable experimental models....

Factor XIa Inhibitor Approved: How Asundexian Compares With Milvexian

The first factor XIa inhibitor approved in the US is Bayer’s asundexian, sold as Sunharbo. It cannot yet be compared directly with milvexian, the rival from Bristol Myers Squibb and Johnson & Johnson. No head-to-head trial exists, and milvexian’s stroke results...

Longevity Science Is Advancing. Can Clinical Care Keep Up?

The search to live longer is not new, but we are no longer looking for a hypothetical fountain of youth. Over the past few decades, research into metabolic health, longevity biomarkers, and more has led to longevity breakthroughs that open up new possibilities for...

Three Grant Budget Rules That Quietly Cost Life Science SMEs Money

Most biotech and medtech teams that lose grant money do not lose it by being ineligible. They lose it by putting a correct cost in the wrong line. The three grant budget rules below come up in almost every budget review: one from Horizon Europe, one from US federal...

GLP-1 Medications List: Every Approved GLP-1 Receptor Agonist Compared (2026)

Regulatory status checked on 11 November 2026. Seven molecules make up the approved GLP-1 class in the US, Europe and the UK. They differ in dosing, in whether they are injections or tablets, and in the conditions they treat. This GLP-1 medications list covers every...

What It Takes To Move Biomanufacturing Toward Commercial Scale

Scientific breakthroughs get attention for good reason. They are the moments when something that did not exist before suddenly becomes possible. But anyone who has spent time trying to commercialize biotechnology learns another lesson pretty quickly: proving that...

GLP-1 Vision Loss: What Does the FDA’s New NAION Warning Mean?

The FDA now requires a NAION warning on every GLP-1 drug. This article sets out what the trial and Sentinel data show, how Europe and the UK compare, and what remains unknown.

    ANI Egetis Offer: What Is ANI Paying and When Could It Close?

    The ANI Egetis offer pays SEK 11.25 a share in cash, about $560 million in total. See the premiums, conditions and expected timetable.

      The Healthcare AI That Wins Won’t Be the One With the Best Demo

      Healthcare has no shortage of impressive AI demos. Scaling healthcare AI is another matter. A model can summarize a chart in seconds. An ambient tool can generate a clinical note from a conversation. An AI agent can identify a denied claim or suggest the next...

      Lilly vs Novo in 2026: How the Obesity Market Has Shifted

      Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

      Povetacicept FDA Decision: Will Vertex Win Approval by 30 November?

      Vertex’s povetacicept FDA decision is due 30 November 2026. See what the RAINIER data, priority review and rival approvals say about IgAN.

        Want to Be Part of the Next Chapter in Life Sciences Media?

         

        LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

         

         

        Don’t wait for the media to pick up your story. Be the media.

        See More Articles

        Want to Be Part of the Next Chapter in Life Sciences Media?

         

        LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

         

         

        Don’t wait for the media to pick up your story. Be the media.